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Cancer cells often have characteristic changes in metabolism. Cellular proliferation, a common feature of
all cancers, requires fatty acids for synthesis of membranes and signaling molecules. Here, we provide a
view of cancer cell metabolism from a lipid perspective, and we summarize evidence that limiting fatty
acid availability can control cancer cell proliferation.Introduction
Although cancers are hugely diverse in type and etiology, cancer
cells frequently share the attribute of metabolic abnormalities.
For example, glucose metabolism is commonly altered to
decouple glycolysis from pyruvate oxidation (theWarburg effect)
so that carbohydrates are not used for maximal ATP generation
via mitochondrial respiration, despite high oxygen availability. A
better understanding of these metabolic changes has prompted
new approaches toward cancer therapy (reviewed in Hsu and
Sabatini, 2008; Schulze and Harris, 2012).
Alterations in fatty acid (FA) metabolism in cancer cells have
received less attention but are increasingly being recognized.
FAs consist of a terminal carboxyl group and a hydrocarbon
chain, mostly occurring in even numbers of carbons, that can
be either saturated or unsaturated. They are required for energy
storage, membrane proliferation, and the generation of signaling
molecules.
Here, we provide a brief review of metabolism in cancer cells,
focusing on pathways of FA synthesis and storage. Furthermore,
we examine a model for attenuating cancer cell proliferation and
metastasis by manipulating FA metabolism to diminish FA avail-
ability. Due to the great diversity of cancer cells, our perspective
is meant to be provocative, not universal. Nevertheless, our
intention is to provide a framework for the generation of new
ideas on how tomanipulate fatty acidmetabolism in cancer cells.
Alterations in Energy Metabolism in Cancer Cells
Cancer is fundamentally a disorder of cell growth and prolifera-
tion, which requires cellular building blocks, such as nucleic
acids, proteins, and lipids. Cancer cells often have perturbed
metabolism that allows them to accumulate metabolic interme-
diates as sources of these building blocks.
The most understood metabolic perturbation in cancer cells is
the Warburg effect, an energetically wasteful alteration to
glucose metabolism in which cancer cells use carbon from
glucose to build other molecules instead of completely oxidizing
them to carbon dioxide (Warburg, 1956). During normal cellular
metabolism in the presence of oxygen, glucose undergoes
glycolysis in the cytoplasm to produce pyruvate. After import
into mitochondria, pyruvate is oxidized to acetyl-CoA, whichthen enters the Krebs cycle to produce reducing equivalents
for oxidative phosphorylation (Figure 1). When oxygen is limiting,
excess pyruvate is fermented to lactate in the cytoplasm. Differ-
entiated cells typically use oxidative phosphorylation because of
its efficiency, with one glucose molecule undergoing complete
oxidation to yield 36 ATP molecules versus 2 ATP that are
obtained from anaerobic glycolysis. The Warburg effect is the
use of fermentation even in the presence of oxygen and is char-
acterized by an increase in glucose uptake and consumption, a
decrease in oxidative phosphorylation, and the production of
lactate.
Another commonly observed metabolic alteration in cancer is
increased glutamine metabolism. In mammalian cells, glutamine
is a major energy substrate through its metabolism to produce
a-ketoglutarate, which feeds into the Krebs cycle. Glutamine-
derived a-ketoglutarate contributes to the production of citrate
by forward flux through the Krebs cycle and malic enzyme-
dependent production of pyruvate (DeBerardinis et al., 2007).
Glutamine can also be converted to citrate by the reversal of
the Krebs cycle reactions catalyzed by isocitrate dehydrogenase
and aconitase (Wise et al., 2008; Mullen et al., 2012; Metallo
et al., 2012). Citrate can then be used for the production of
acetyl-groups for FA synthesis (see below).
Lipidmetabolism is also altered in rapidly proliferating cells (for
general reviews, see Swinnen et al., 2006; DeBerardinis and
Thompson, 2012; Santos and Schulze, 2012). Here we focus
on cancer and FA metabolism. In cancer cells, carbon must be
diverted from energy production to FAs for biosynthesis of mem-
branes and signaling molecules. The bulk of cell membrane
lipids are phospholipids (PLs), such as phosphatidylcholine
(PC) and phosphatidylethanolamine (PE), in addition to other
lipids, such as sterols, sphingolipids, and lyso-PLs. All of these
lipids are derived in part from acetyl CoA, and many contain
FAs. The FA building blocks come from either exogenous sour-
ces or from de novo FA synthesis. While most normal human
cells prefer exogenous sources, tumors synthesize FA de novo
(Medes et al., 1953) and often exhibit a shift toward FA synthesis
(Ookhtens et al., 1984). To enter the bioactive pool, FAs require
‘‘activation’’ by covalent modification by CoA via fatty acyl-CoA
synthetases. Once in the active pool, FAs can be esterified withCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 153
Figure 1. Overview of Cellular Fatty Acid
Metabolism
See text for description of depicted pathways.
Enzymes are in bold. Enzymes with boxes around
them are membrane localized.
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sterol esters (SEs), respectively, and then stored in lipid droplets
(LDs) (see Figure 1). Within cells, FAs can have many fates,
including being incorporated into membrane, storage, or
signaling lipids, or oxidized to carbon dioxide as an energy
source.
Although this review focuses on de novo FA synthesis path-
ways, some tumors scavenge lipids from their environment,
rendering FA uptake pathways as a potential target. For
example, fatty acid binding protein 4 (FABP4), a lipid chaperone,
is implicated in providing FAs from surrounding adipocytes for
ovarian tumors (Nieman et al., 2011). Also, prostate cancer cells
show reduced viability in the presence of FASN (C75) or ACLY154 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.(SB-204990) inhibitors only when
cultured in the absence of lipoproteins,
an exogenous lipid source (Ros et al.,
2012). CD36, a widely expressed trans-
membrane protein with diverse functions
that include fatty acid uptake, has been
implicated in breast cancer, and
decreased levels of CD36 in stromal tis-
sue are correlated with early steps in
tumorigenesis (DeFilippis et al., 2012). It
is noteworthy that in vitro conditions for
cell culture experiments are likely to be
different than in vivo conditions, where
exogenous uptake may be more impor-
tant in some cancers.
Limiting Supplies of Fatty Acids to
Limit Cancer Cell Proliferation
Since FAs are essential for cancer cell
proliferation, limiting their availability
could provide a therapeutic strategy.
From the perspective of lipid metabolism,
limiting FA availability could be achieved
in several ways: (1) blocking FA synthesis,
(2) increasing FA degradation via oxida-
tion, (3) diverting FAs to storage, or (4)
decreasing FA release from storage
(Figure 2). Limiting FAs through these
mechanisms could be accomplished in
isolation or in a combinatorial manner.
Using this as a framework, we review ev-
idence relevant to this model.
Blocking Fatty Acid Synthesis
The simplest way to reduce FA levels is to
block their synthesis. Glucose meta-
bolism feeds into FA metabolism at the
point of citrate, an intermediate in the
Krebs cycle (see Figure 1). Several stepsare required to convert carbons from citrate to bioactive fatty
acids. These steps involve ATP citrate lyase (ACLY, ACL, or
ATPCL), acetyl-CoA carboxylase (ACC), fatty acid synthase
(FASN or FAS), and acyl-CoA synthetases, also known as fatty
acid-CoA ligase (ACS, ACSL, or FACL). In the model of
decreasing FA availability, inhibiting these enzymes would limit
cancer cell growth. Important for the clinical significance of these
strategies, many inhibitors of these enzymes have minimal ef-
fects on noncancer cells.
The subcellular localization of citrate determines its metabolic
fate: mitochondrial citrate feeds into the Krebs cycle, and cyto-
plasmic citrate feeds into FA synthesis. Citrate is transported
across the inner mitochondrial membrane for use in the
Figure 2. Model Showing How Limiting
Fatty Acids in the Cell Might Limit Cancer
Cell Proliferation
This may be done by (1) blocking the synthesis of
FA, (2) increasing the rate of FA degradation, (3)
increasing FA storage in neutral TG, and/or (4)
decreasing FA release from storage.
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(citrate carrier). CIC levels are elevated in various cancer cell
lines and tumors in a manner correlated with poor outcomes,
and the inhibition of transport by benzene-tricarboxylate analog
(BTA) shows antitumor effects in various tumor types and in vivo
in xenograft mice (Catalina-Rodriguez et al., 2012).
ACLY
ACLY bridges glucose metabolism and FA metabolism by con-
verting six-carbon citrate to oxaloacetate and two-carbon
acetyl-CoA, the precursor for FA synthesis. Knockdown of
ACLY reduces the ability of cells to metabolize glucose to lipid,
as shown by shRNA in murine lymphoid cells (Bauer et al.,
2005) and siRNA in human adenocarcinoma cells (HatzivassiliouCell Metabolism 1et al., 2005). This alteration in metabolism
impairs murine tumorigenesis and pre-
vents xenograft tumor formation by hu-
man cancer cells when ACLY is knocked
down by shRNA (Bauer et al., 2005; Hat-
zivassiliou et al., 2005) or siRNA (Migita
et al., 2008) or chemically inhibited by
SB-204990 (Hatzivassiliou et al., 2005).
While ACLY is a promising therapeutic
target, its product acetyl-CoA is an
important metabolite for many molecules
and a substrate for the acetylation of pro-
teins and nucleic acids (Wellen et al.,
2009). Thus, inhibiting its production
may have consequences for other meta-
bolic pathways as well.
ACC
ACC carboxylates acetyl-CoA to form
malonyl-CoA, catalyzes the committed
step, and is the most highly regulated
enzyme in the fatty acid synthesis
pathway (reviewed in Wakil and Abu-El-
heiga, 2009). ACC is positively and
allosterically regulated by citrate and
glutamate and negatively and allosteri-
cally regulated by long- and short-chain
fatty acyl-CoAs such as palmitoyl-CoA.
ACC is inactivated by phosphorylation
by AMP-activated protein kinase
(AMPK) and potentially regulated by
many other kinases. There are two
ACCs in the human genome, ACC1
(ACCa or ACACA) and ACC2 (ACCb or
ACACB). ACC1 is highly enriched in lipo-
genic tissues, and ACC2 occurs in oxida-
tive tissues. Because they are primarily
found in different specialized tissues,ACC1 and ACC2 have different metabolic roles. Malonyl-CoA
made by ACC1 is thought to serve as a substrate for FA synthe-
sis, whereas the malonyl-CoA made by ACC2 serves to inhibit
CPT1 (see next section), thus preventing FA degradation.
Knockdown of ACC1 by siRNA induces apoptosis in prostate
cancer (Brusselmans et al., 2005) and breast tumor (Chaje`s et al.,
2006) cells but not in control nonmalignant cells. Chemical inhi-
bition of ACC1 and ACC2 by soraphen-A showed similar results
in prostate cancer cells (Beckers et al., 2007). However, a con-
tradictory result was observed with ACC inhibition by TOFA (5-
(tetradecyloxy)-2-furoic acid) in breast cancer cells (Pizer et al.,
2000). This may be attributable to epidermal growth factor re-
ceptor (EGFR) activation, as TOFA was observed by another8, August 6, 2013 ª2013 Elsevier Inc. 155
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toma cell lines while not affecting non-EGFR-activated cell lines
(Guo et al., 2009a). The situation is further complicated by the
observation that silencing of ACC1 or ACC2 accelerated tumor
growth in lung cancer cells by promoting NADPH-dependent
redox balance (Jeon et al., 2012).
While some aspects of the role of ACC in cancer cells still need
to be elucidated, ACC activity might be controlled by promoting
ACC phosphorylation. AMPK is activated by drugs, such asmet-
formin, already widely used to treat diabetes. There is experi-
mental evidence in vitro and in vivo in mice and humans, mainly
in solid tumor models, that metformin treatment has antitumor
activity, and clinical trials to further explore efficacy are under-
way (Pollak, 2012).
MCD
Malonyl-CoA decarboxylase (MCD) decarboxylates malonyl-
CoA to acetyl-CoA, essentially reversing the reaction catalyzed
by ACC. Thus, it is surprising that MCD inhibition yields data
similar to ACC. siRNA against MCD and MPA treatment, a
small-molecule inhibitor of MCD, are cytotoxic to breast cancer
lines but not fibroblasts (Zhou et al., 2009).
FASN
FASN catalyzes successive condensation reactions to form a
fatty acid frommalonyl-CoA and acetyl-CoA substrates, produc-
ingmainly 16-carbon palmitate. It is perhaps themost studied FA
metabolic enzyme with respect to cancer. Increased fatty acid
synthesis due to increased levels of FASN has been observed
in a multitude of cancers and is strongly correlated with a poor
prognosis in many instances (reviewed in Menendez and Lupu,
2007). RNAi against FASN decreases levels of TG and phospho-
lipids and inhibits cell growth and apoptosis in cells derived from
a lymph node metastasis of prostate carcinoma (LNCaP) cells
with no effects on growth rate or viability of nonmalignant
cultured skin fibroblasts (De Schrijver et al., 2003). In many re-
ports, chemical inhibitors of FASN preferentially killed cancer
cells (reviewed in Lupu and Menendez, 2006). FASN is a partic-
ularly appealing therapeutic target because most cancer cells
depend upon FASN-mediated de novo FA synthesis, whereas
most noncancer cells prefer exogenous FA. However, cell death
induced after FASN inhibition might be due to the toxic accumu-
lation of malonyl-CoA rather than a lack of FA (Pizer et al., 2000).
Moreover, some inhibitors of FASN show severe side effects in
animal models, including dramatic weight loss (Loftus et al.,
2000), and FASN is required for adult neuronal stem cell function
(Knobloch et al., 2013).
ACS
For FAs to enter bioactive pools, they must be activated by ACS
enzymes, which generate FA-CoA. Bioactive FAs also contribute
to protein palmitoylation, a posttranslational modification that is
important in certain cancers (Resh, 2012). Mammals have five
ACS isoforms (ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6)
and also have fatty acid transport proteins with acyl-CoA synthe-
tase activity. ACSL4 is upregulated in some colon adenocarci-
nomas (Cao et al., 2000), and ACSL5 levels are increased in
glioblastomas (Yamashita et al., 2000). Overexpression of
ACSL4 promotes tumor cell survival by preventing apoptosis,
likely through depletion of unesterified arachidonic acid (AA),
which yields a proapoptotic signal (Cao et al., 2000). Chemical
inhibition of ACS by Triacsin C (inhibitor of ACSL1, ACSL3, and156 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.ACSL4 but not ACSL5 or ACSL6 [Van Horn et al., 2005; Kim
et al., 2001]) preferentially induces apoptotic cell death in lung,
colon, and brain cancer cells (Mashima et al., 2005). Several thia-
zolidinediones (TZDs) directly bind and inhibit rat ACSL4 (but not
ACSL1 or ACSL5) in vitro (Kim et al., 2001). TZDs activate perox-
isome proliferator-activated receptors (PPARs), particularly
PPARg, and are already inwide use for the treatment of diabetes.
TZD use is correlated with decreased incidence of certain can-
cers in diabetics in what is likely to be a PPARg-independent
manner (Weng et al., 2006). When considering treatment through
inactivation of ACS, it is important to note that different drugs
have different isoform specificities, so they may have differential
effects, as the various isoforms have different tissue specificities,
responses to nutritional state (Mashek et al., 2006), and
preferred substrates (notably, ACSL4 prefers AA).
SCD
SCD catalyzes the introduction of double bonds into short-chain
FAs in the C9 position (mainly converting stearoyl-CoA to oleoyl-
CoA) (Paton and Ntambi, 2009). This alters the physical proper-
ties of FAs and has profound effects on lipid function. There are
two isoforms of SCD in human cells (SCD1 and SCD5). SCD
expression and activity is upregulated in some cancers, and its
importance for cancer biology is increasingly recognized (Igal,
2010). Inhibition of SCD function causes cell death in cancer
cells, probably by inducing the accumulation of unsaturated fatty
acids (Ariyama et al., 2010). Pharmacological inhibition of SCD
limits tumor growth in preclinical cancer models (Fritz et al.,
2010) without affecting overall body weight (Roongta et al.,
2011). Since cancer cells rely considerably on de novo FA syn-
thesis, SCD inhibition will likely show some degree of selectivity.
FAs are also substrates for sphingolipid synthesis. While
sphingolipid metabolism is not a focus of this review, it is note-
worthy that specific sphingolipids, such as ceramides and sphin-
gosine-1-phosphate, are bioactive signaling molecules that
generally suppress or promote tumors, respectively (Ogretmen
and Hannun, 2004). Moreover, accumulation of ceramides is
implicated in the therapeutic effects of various chemothera-
peutic treatments of cancer.
Blocking Expression of Fatty Acid Synthesis Genes
In addition to directly targeting enzymes of FA synthesis,
their activities could be reduced by reducing transcription levels.
The master transcriptional regulators of FA synthesis are sterol
regulatory element-binding protein 1 (SREBP-1) transcription
factors (Horton et al., 2002). SREBP-1 has two isoforms:
SREBP-1a is the predominant isoform inmost cultured cell lines,
and SREBP-1c is predominant in liver and most tissues. At
normal levels, SREBP-1c activates the FA biosynthetic pathway
with responsive genes including ACLY, ACC, FAS, SCD-1, and
GPAT. Therefore, inhibiting SREBP-1 in cancer cells could
decrease FA synthesis gene expression and possibly prevent
cancer cell proliferation. Indeed, shRNA knockdown of
SREBP-1 decreases abundance of ACC and FAS and promotes
tumor cell death of glioblastoma cells that overexpress SREBP-1
because of constitutively active EGFR, and 25-hydroxycholes-
terol (25-HC), an inhibitor of activation of SREBP-1 and
SREBP-2, causes cell death in high EGFR (and therefore high
SREBP-1) expressing cancer cell lines (Guo et al., 2009b). Addi-
tionally, higher levels of SREBP-1 are seen in prostate cancer
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tate cancer progression to androgen independence (Ettinger
et al., 2004). Interestingly, recent work suggests that a mecha-
nism for SREBP-1 repression preventing cancer cell proliferation
is through loss of SCD-1 and FA desaturation, thereby causing
lipotoxicity due to abnormally high levels of saturated FAs (Wil-
liams et al., 2013; Griffiths et al., 2013). Inhibition of SREBP by
25-HC, fatostatin, and FGH10019 all cause a decrease in
expression of SREBP-1 and SREBP-2 target genes and signifi-
cantly reduce cellular growth in a variety of cancer cell lines (Wil-
liams et al., 2013), and SREBP1 knockdown by shRNA reduces
tumor growth in vivo in nude mice (Griffiths et al., 2013).
Further upstream, SREBP transcription factors and FA synthe-
sis can be regulated by many signaling pathways, including
growth factor signaling, which is reviewed in depth elsewhere
(Shao and Espenshade, 2012; Kumar-Sinha et al., 2003; Peter-
son et al., 2011; Laplante and Sabatini, 2009; Lewis et al.,
2011). Another transcription factor, liver X-activated receptor
(LXR), activates fatty acid synthesis by inducing SREBP-1c
(Liang et al., 2002). Therefore, cancer cell proliferation might be
attenuated by preventing LXR activation. However, activation
of LXR, particularly through T0901317, inhibits cancer cell prolif-
eration in breast, colon, and prostate cancers (Viennois et al.,
2012). These findings likely reflect functions of LXR other than
regulating FA synthesis.
Increasing Fatty Acid Degradation
FA levels might be decreased in cancer cells by increasing the
rate at which they are degraded. Activated FAs are broken by
mitochondrial b-oxidation. FA-CoAs are transported from the
cytosol across the outer mitochondrial membrane after they
are converted to FA carnitines by carnitine palmitoyl transferase
1 (CPT1). Within the mitochondria, FAs are then repeatedly
cleaved to produce acetyl-CoAs that feed into the Krebs cycle
and produce reducing equivalents for oxidative phosphorylation.
Increasing FA oxidation to limit FA abundance could in theory be
beneficial, but data from experiments testing this idea aremixed.
CPT1
CPT1 is the first and rate-limiting step of fatty acid transport into
mitochondria for oxidation to carbon dioxide. It is inhibited by
malonyl-CoA. b-oxidation of FAs is increased when ACC2 is in-
hibited because of the depletion of malonyl-CoA, the direct
product of ACC. Therefore, the attenuation of cancer cell prolif-
eration by inhibiting ACC (discussed previously) may also be due
in part to an increase in degradation of FAs.
It is yet unclear whether increased FA oxidation in cancer cells
will block proliferation. Cancer types likely differ in their clinical
response to increasingFAoxidation, dependingupon their energy
requirements and ACC isoform expression patterns. In some
types, increased FA oxidation may diminish FA availability and
be beneficial. On the other hand, etomoxir, an inhibitor of CPT1,
and ranolazine, an indirect inhibitor of FA oxidation, may kill can-
cer cells (Samudio et al., 2010; Pike et al., 2011). A further caveat
of increasing the FA oxidation rate is that it could increase cellular
ATP levels, thus providing energy for further cellular proliferation.
Indeed, CPT1C, the brain isoform of CPT1, is important for the
survival of cancer cells under energy stress (Zaugg et al., 2011).
PPARa is a major transcriptional regulator of FA oxidation with
activation inducing oxidation. In keeping with the uncertaintyregarding the role of FA oxidation in cancer cell proliferation,
extended PPARa activation causes hepatocellular carcinoma
in mice and rats by an unclear mechanism that involves pertur-
bation of the cell cycle and production of reactive oxygen
species (reviewed by Michalik et al., 2004). However, humans
taking PPARa agonists do not develop similar cancers, and in
fact, PPARa activation inhibits tumor growth in several models
(reviewed in Yokoyama and Mizunuma, 2010).
Diverting Fatty Acids to Storage
Once made, FAs can be used for membrane lipid synthesis,
degraded, or stored. Conceivably, increased storage of FAs in
neutral lipids, such as TGs or sterol esters, could lead to a reduc-
tion in FAs available for use as membrane building blocks or
signaling lipids and inhibit cellular proliferation. Most cells store
FAs in TGs in the cytosolic lipid droplet (LD), an organelle whose
major function is lipid storage (see Farese and Walther, 2009).
The role of LDs in cancer cells is unclear. While increased
numbers of LDs have been reported in many cancer cells (re-
viewed in Bozza and Viola, 2010), and this accumulation has
been proposed to be pathogenic, the accumulation of LDs per
se might not be the culprit. The readily available pool of FAs
that they represent might be pathogenic. LD accumulation might
also reflect a cellular response to stress (Hapala et al., 2011).
Future studies should also carefully delineate whether LD accu-
mulation occurs within cancer cells or in surrounding cells.
The major TG synthesis pathway is known as the Kennedy or
glycerol-phosphate pathway. It condenses FAs with glycerol 3-
phosphate using the enzymes glycerol-3-phosphate acyltrans-
ferase (GPAT), acylglycerolphosphate acyltransferase (AGPAT),
phosphatidic acid phosphohydrolase (lipin or PAP), and diacyl-
glycerol acyltransferase (DGAT). The products of all but the
most distal enzyme (DGAT) feed into PL synthesis. Therefore,
GPAT, AGPAT, and lipinmight be inhibited to limit PL production,
while efforts to increase FA storage would be focused on acti-
vating DGAT. Additionally, the potential benefits of increasing
FA storage may only be realized while concomitantly inhibiting
the release of FA from storage.
AGPAT
AGPAT esterifies lysophosphatidic acid (LPA) and a FA-CoA to
form phosphatidic acid (PA). Theremay be asmany as 11 human
AGPATs. Elevated AGPAT2 expression is associated with poor
prognosis of ovarian cancers, and AGPAT2 inhibitors have anti-
tumor activity in xenograft mice (reviewed in Takeuchi and Reue,
2009). Additionally, AGPAT9 and AGPAT11 are upregulated in a
variety of cancers (reviewed in Agarwal, 2012). As with any
enzyme with multiple isoforms, differences in expression
patterns of the isoforms may have a profound influence on the
effectiveness of inhibition/activation of a particular isoform in a
particular cancer.
PAP
Lipin removes a phosphate group from PA to form diacylglycerol
(DG). It is one of the least-studied enzymes in the lipid storage
pathway with respect to cancer, and little is known about how
blocking or overexpressing this step of lipid synthesis affects
cancer progression. However, lipin is involved in the regulation
of the activity of SREBP, a family of transcription factors that
regulate the expression of many enzymes involved in fatty acid
and cholesterol biosynthesis (Ishimoto et al., 2009). Lipin isCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 157
Table 1. Examples of Chemical Inhibitors of Lipid Enzymes that Could Reduce Fatty Acid Availability
Enzyme Inhibitor Comments Selected References
ACC Soraphen-A Beckers et al., 2007
TOFA (5-(tetradecyloxy)-2-furoic acid) Pizer et al., 2000; Guo et al., 2009a
A-769662 Go¨ransson et al., 2007
Metformin Indirect, activates AMPK, FDA approved Pollak, 2012
AICAR Indirect, activates AMPK Jose et al., 2011; Swinnen et al., 2005
ACLY SB-204990 Hatzivassiliou et al., 2005; Ros et al., 2012
LY294002 Indirect, PI3K inhibitor Migita et al., 2008
ACS Triacscin C Mashima et al., 2005
Thiazolidinediones (TZDs) ACSL4 specific, also activates PPARg, FDA
approved
Kim et al., 2001
AGPAT CT-32501 AGPAT2 specific Takeuchi and Reue, 2009
CKa TCD-717 Currently in phase I trials http://clinicaltrials.gov/show/NCT01215864
MN58B Glunde et al., 2011
CIC Benzene-tricarboxylate analog (BTA) Catalina-Rodriguez et al., 2012
CPT1 Etomoxir Samudio et al., 2010; Pike et al., 2011
Ranolazine FDA approved Samudio et al., 2010
FASN Cerulenin and its derivative C75 Lupu and Menendez, 2006; Ros et al., 2012
Orlistat FDA approved Lupu and Menendez, 2006
Flavonoids Naturally occurring Lupu and Menendez, 2006
Epigallocatechin-3-gallate (EGCG) Found in green tea Lupu and Menendez, 2006
MAGL JZL184 Nomura et al., 2010
SCD BZ36 Fritz et al., 2010
A939572 Roongta et al., 2011
SREBP Fatostatin Inhibits processing of SREBP-1 and SREBP-2 Williams et al., 2013
FGH10019 Inhibits processing of SREBP-1 and SREBP-2 Williams et al., 2013; Kamisuki et al., 2011
Shown are selected inhibitors for enzymes mentioned in text.
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mycin complex 1, resulting in activation of SREBP transcriptional
activity (Peterson, et al., 2011). Modulating lipin activity may
therefore have significant effects on cellular lipid homeostasis.
DGAT
DGAT enzymes esterify DG and a FA-CoA to form TG. Mammals
have two DGATs (DGAT1 and DGAT2). DGAT catalyzes the only
dedicated step in TG formation and thus provides a key target for
decreasing available lipids by increasing lipid storage. Trans-
formed human fibroblasts overexpressing DGAT1 had increased
TG and decreased phospholipids, as well as reduced prolifera-
tion and invasiveness (Bagnato and Igal, 2003). Unpublished
data from the Farese laboratory suggest that DGAT1-deficient
mice have increased levels of LPA and PGE2 in mammary fat
and develop some breast cancers more rapidly (S. Cases, per-
sonal communication). DGAT1 inhibition might also favor the
accumulation of its substrate diacylglycerol in cells, which might
have signaling effects. These findings would suggest caution,
from a cancer standpoint, for the use of DGAT1 inhibitors, which
are being explored clinically for use in metabolic diseases.
PLs are the other major products of glycerolipid synthesis and
are important for membrane expansion in rapidly proliferating
cells. The major mammalian membrane phospholipid is PC.
Many cancers have increased PC levels and increased activity
of any of several enzymes in the PC synthesis pathway, while158 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.inhibition or knockdown of many of the enzymes decreases can-
cer phenotypes (Glunde et al., 2011). An inhibitor of choline
kinase alpha, the first step of choline activation for PC synthesis,
is currently in Phase I trials for use against advanced solid tumors
(http://clinicaltrials.gov/show/NCT01215864).
Blocking Fatty Acid Release from Storage
Once stored, FAs can be released for use by specific lipases. By
preventing lipolysis, the active FA pool available for cancer cell
proliferation might be decreased. FAs derived from lipolysis
can also serve as precursors for important signaling lipids (see
Wymann and Schneiter, 2008). Most knowledge on lipolysis is
derived from work on adipocytes where each TG molecule in
the LD can be fully hydrolyzed to release three FAs by the
sequential action of adipose triglyceride lipase (ATGL), hormone
sensitive lipase (HSL), and monoacylglycerol lipase (MAGL).
Although each of these lipases also has important functions in
other tissues, it is yet unclear whether other lipases might oper-
ate in other cell types. Currently, most data addressing lipases
and cancer are for MAGL.
MAGL
MAGLhydrolyzes the final FA fromMG leaving the glycerol back-
bone. MAGL expression and activity are increased in several
aggressive cancer cell lines and primary tumors (Nomura et al.,
2010). Knockdown and chemical inhibition of MAGL by JZL184
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and ovarian cancer cells in vitro and in vivo, while overexpression
showed the opposite phenotype. Interestingly, a high-fat diet in
mice reversed the reduced tumor growth of MAGL-inhibited tu-
mors in mice. This observation raises the question of whether
targeting lipid metabolism for cancer therapy may only be effec-
tive in combination with specific dietary regimes. Additionally,
MAGL has a role in the regulation of signaling lipids: more inva-
sive tumors have increased LPA and PGE2 levels, and those are
decreased in the presence of MAGL inhibitors.
ATGL and HSL
Although their roles in cancer cell proliferation are unclear, ATGL
and HSL play an important role in cancer cachexia, a wasting
syndrome that is an adverse prognostic factor in cancer. Cancer
patients with cachexia show increased HSL and ATGL activity
when compared to non-cancer patients, and genetic ablation
of ATGL (and HSL to a lesser extent) protects mice from can-
cer-associated loss of adipose tissue and skeletal muscle (Das
et al., 2011). Therefore, pharmacological inhibition of ATGL
and/or HSL may help to prevent cancer-associated cachexia.Conclusion and Perspective
Cancer cells rely on FAs as cellular building blocks formembrane
formation, energy storage, and the production of signaling mol-
ecules. Our review highlights this requirement and provides a
framework for the investigation of limiting the supply of FAs. If
the model that FAs are required for cancer cell proliferation is
correct, cancer cells might be targeted at multiple points within
the pathway of FA metabolism to subvert rapid proliferation,
andmany chemical inhibitors for specific steps already exist (Ta-
ble 1). Much like glucose metabolism, targeting FA metabolism
might be more selective for highly proliferative cells. Alterna-
tively, delivery of FA metabolism inhibitors might be done in a
cell-specific and targeted manner.
Cancers are diverse in type and underlying genetic alterations.
Lipid metabolism is complex, with many different feedback
mechanisms and points of regulation. Additionally, most of the
lipid metabolic enzymes have multiple isoforms, and these
may be coupled to different lipid metabolic processes and can
have different cellular localization or tissue distribution. There-
fore, successful therapies may be dependent upon understand-
ing the specific metabolic abnormalities for a particular type of
cancer.ACKNOWLEDGMENTS
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